These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 17905583)

  • 21. Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 1: 2-Pyridinylguanidines.
    Barber CG; Dickinson RP; Horne VA
    Bioorg Med Chem Lett; 2002 Jan; 12(2):181-4. PubMed ID: 11755349
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lipophilic G-quadruplexes are self-assembled ion pair receptors, and the bound anion modulates the kinetic stability of these complexes.
    Shi X; Mullaugh KM; Fettinger JC; Jiang Y; Hofstadler SA; Davis JT
    J Am Chem Soc; 2003 Sep; 125(36):10830-41. PubMed ID: 12952462
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is inhibition process better described with MD(QM/MM) simulations? The case of urokinase type plasminogen activator inhibitors.
    Barbault F; Maurel F
    J Comput Chem; 2012 Mar; 33(6):607-16. PubMed ID: 22241532
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High quality structure of cleaved PAI-1-stab.
    Dewilde M; Strelkov SV; Rabijns A; Declerck PJ
    J Struct Biol; 2009 Feb; 165(2):126-32. PubMed ID: 19059484
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure-directed discovery of potent non-peptidic inhibitors of human urokinase that access a novel binding subsite.
    Nienaber VL; Davidson D; Edalji R; Giranda VL; Klinghofer V; Henkin J; Magdalinos P; Mantei R; Merrick S; Severin JM; Smith RA; Stewart K; Walter K; Wang J; Wendt M; Weitzberg M; Zhao X; Rockway T
    Structure; 2000 May; 8(5):553-63. PubMed ID: 10801494
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of a novel albumin-binding prodrug that is cleaved by urokinase-type-plasminogen activator (uPA).
    Chung DE; Kratz F
    Bioorg Med Chem Lett; 2006 Oct; 16(19):5157-63. PubMed ID: 16875815
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hydrogen-bonded supramolecular motifs in 2-amino-4,6-dimethoxypyrimidinium picrate and pyrimethaminium picrate dimethyl sulfoxide solvate.
    Thanigaimani K; Subashini A; Muthiah PT; Lynch DE; Butcher RJ
    Acta Crystallogr C; 2009 Feb; 65(Pt 2):o42-5. PubMed ID: 19190385
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A cyclic peptidylic inhibitor of murine urokinase-type plasminogen activator: changing species specificity by substitution of a single residue.
    Andersen LM; Wind T; Hansen HD; Andreasen PA
    Biochem J; 2008 Jun; 412(3):447-57. PubMed ID: 18318660
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Coordination of Ce(III) and Nd(III) with pentaethylene glycol in the presence of picrate anion: spectroscopic and X-ray structural studies.
    Kusrini E; Saleh MI; Lecomte C
    Spectrochim Acta A Mol Biomol Spectrosc; 2009 Sep; 74(1):120-6. PubMed ID: 19560960
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 2: (3-Substituted-5-halo-2-pyridinyl)guanidines.
    Barber CG; Dickinson RP
    Bioorg Med Chem Lett; 2002 Jan; 12(2):185-7. PubMed ID: 11755350
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Distinctive binding modes and inhibitory mechanisms of two peptidic inhibitors of urokinase-type plasminogen activator with isomeric P1 residues.
    Jiang L; Zhao B; Xu P; Sørensen HP; Jensen JK; Christensen A; Hosseini M; Nielsen NC; Jensen KJ; Andreasen PA; Huang M
    Int J Biochem Cell Biol; 2015 May; 62():88-92. PubMed ID: 25744057
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of a novel conformational equilibrium in urokinase-type plasminogen activator.
    Kromann-Hansen T; Louise Lange E; Peter Sørensen H; Hassanzadeh-Ghassabeh G; Huang M; Jensen JK; Muyldermans S; Declerck PJ; Komives EA; Andreasen PA
    Sci Rep; 2017 Jun; 7(1):3385. PubMed ID: 28611361
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structural basis of specificity of a peptidyl urokinase inhibitor, upain-1.
    Zhao G; Yuan C; Wind T; Huang Z; Andreasen PA; Huang M
    J Struct Biol; 2007 Oct; 160(1):1-10. PubMed ID: 17692534
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer.
    Steiner E; Pollow K; Hasenclever D; Schormann W; Hermes M; Schmidt M; Puhl A; Brulport M; Bauer A; Petry IB; Koelbl H; Hengstler JG
    Gynecol Oncol; 2008 Mar; 108(3):569-76. PubMed ID: 18222533
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors.
    Gutova M; Najbauer J; Frank RT; Kendall SE; Gevorgyan A; Metz MZ; Guevorkian M; Edmiston M; Zhao D; Glackin CA; Kim SU; Aboody KS
    Stem Cells; 2008 Jun; 26(6):1406-13. PubMed ID: 18403751
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
    Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
    Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R; Schaaf A
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Urokinase-type plasminogen activator and plasminogen-activator-inhibitor type 1 predict metastases in good prognosis breast cancer patients.
    De Cremoux P; Grandin L; Diéras V; Savignoni A; Degeorges A; Salmon R; Bollet MA; Reyal F; Sigal-Zafrani B; Vincent-Salomon A; Sastre-Garau X; Magdelénat H; Mignot L; Fourquet A;
    Anticancer Res; 2009 May; 29(5):1475-82. PubMed ID: 19443353
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Boosting the sensitivity of ligand-protein screening by NMR of long-lived states.
    Salvi N; Buratto R; Bornet A; Ulzega S; Rentero Rebollo I; Angelini A; Heinis C; Bodenhausen G
    J Am Chem Soc; 2012 Jul; 134(27):11076-9. PubMed ID: 22686687
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comment on "Growth and characterization of glycine picrate single crystal" by T. Uma Devi et al. [Spectrochim. Acta A71 (2008) 340-343].
    Petrosyan AM
    Spectrochim Acta A Mol Biomol Spectrosc; 2010 Mar; 75(3):1176. PubMed ID: 20047856
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.